Evidence map›Paper›PMID 41989846›Full record

ArticleJCI insight2026

NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.

Chenfei Huang, Shhyam Moorthy, Qiuli Li, Kazi M Ahmed, Kalil Saab, Defeng Deng, Jiping Wang, Xiayu Rao, Jiexin Zhang, Yuanxin Xi and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Chenfei HuangBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Shhyam MoorthyDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Qiuli LiDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kazi M AhmedBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Kalil SaabBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Defeng DengBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Jiping WangDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiayu RaoDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jiexin ZhangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yuanxin XiDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhiyi LiuDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Noriaki TanakaDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Eve ShinbrotHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA.
Rami SaadeDepartment of Otolaryngology, Lebanese American University, Beirut, Lebanon.
Curtis R PickeringDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tong-Xin XieDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Adel K El-NaggarDepartment of Pathology.
Abdullah A OsmanDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kunal RaiDepartment of Genomic Medicine and MDACC Epigenomics Therapy Initiative.
Patrick A Zweidler-McKayDepartment of Pediatric Leukemia and Lymphoma, and.
John V HeymachDepartment of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren A ByersDepartment of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Faye M JohnsonDepartment of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Vlad C SandulacheBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Jeffrey N MyersDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pedram YadollahiBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Mitchell J FrederickBobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.

Funding

Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancersR01DE030875 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jeffrey Nicholas Myers, Andrew Sikora · 2022 to 2026
$2.8M
NIDCR NIH HHS R01 DE030875
6 · The paper itself

Abstract

Inactivating NOTCH1 mutations in head and neck squamous cell carcinoma (HNSCC) were described over a decade ago, suggesting a tumor suppressor function - unlike its oncogenic role in other tumors. Today, much debate persists regarding a putative oncogenic role in HNSCC as well, with reports that NOTCH1 signaling drives tumor growth and a cancer stem cell (CSC) phenotype. In this work, comprehensive experiments unequivocally demonstrate that NOTCH1 is a tumor suppressor in HNSCC regardless of mutation or activation status and that it reduces CSC frequency. We developed a signature of NOTCH1 activation showing the pathway is associated with very early differentiation, an altered tumor microenvironment, and better prognosis. Clarifying whether NOTCH1 occasionally functions as an oncogenic driver in HNSCC is crucial to prognosis and personalized therapy. The results presented unify the field, reconcile conflicting data, and provide critical insights into the biological and clinical significance of NOTCH1, with broader implications in other squamous carcinomas with NOTCH1 mutations.

Indexed as

Head and Neck NeoplasmsReceptor, Notch1AnimalsCell DifferentiationCell Line, TumorGenes, Tumor SuppressorHumansMaleMiceNeoplastic Stem CellsSignal TransductionSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentNOTCH1 protein, humanReceptor, Notch1Cell biologyHead and neck cancerOncologyStem CellsTumor suppressors

Identifiers

PMID41989846
PMCPMC13313506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.